Low-Volume Lymph Node @entity3 Discovered During Sentinel Lymph Node Mapping for XXXX .

@entity1 @entity5 @entity3 @entity1204
PURPOSE: The aim of this study was to characterize treatment patterns and oncologic outcomes in @entity1 with low-volume lymph node @entity3 ( @entity5 cells [ITCs] and micrometastasis [MM]) discovered during sentinel lymph node (SLN) mapping for @entity1204 . METHODS: We identified @entity1204 cases treated surgically from September 2005 to April 2013 in which SLN mapping was performed. MM was defined as @entity5 within a lymph node measuring >0.2  mm but <2.0  mm, and ITCs were those measuring  <=0.2  mm. RESULTS: Overall, 844 @entity1 , with a median age of 61  years (range 30-90), met the inclusion criteria. Histology was as follows: endometrioid, 724 (85.8  %) @entity1 ; serous, 104 (12.3  %) @entity1 ; and clear cell, 16 (1.9  %) @entity1 . The median number of lymph nodes resected was six (range 0-60), and the median number of SLNs was two (range 0-15). Overall, 753 (89.2  %) @entity1 were node-negative, 23 (2.7  %) had ITCs only, 21 (2.5  %) had MM only, and 47 (5.6  %) had macrometastasis. Adjuvant chemotherapy was administered to 106 (14  %) of 753 node-negative @entity1 , 19 (83  %) of 23 @entity1 with ITCs, 17 (81  %) of 21 @entity1 with MM, and 42 (89  %) of 47 with macrometastasis. Median follow-up was 26  months (range 0-108). Three-year recurrence-free survival was as follows: node-negative @entity1 , 90  % (  1.5); ITCs only, 86  % (  9.4); MM only, 86  % (  9.7); and macrometastasis, 71  % (  7.2) [p  <  0.001]. CONCLUSIONS: @entity1 with ITCs and MM frequently received adjuvant chemotherapy and had improved oncologic outcomes in comparison to those with macrometastasis to the lymph nodes. Further prospective study is needed to determine optimal post-resection management in @entity1 with ITCs or MM alone.
